Aryl-hydrocarbon receptor as a potential target for anticancer therapy

Vorontsova J.E.1 , Cherezov R.O.1, Kuzin B.A.1, Simonova O.B.1

1. Koltzov Institute of Developmental Biology of Russian Academy of Sciences, Moscow, Russia
Section: Review
DOI: 10.18097/PBMC20186405397      PubMed Id: 30378556
Year: 2018  Volume: 64  Issue: 5  Pages: 397-415
Aryl-hydrocarbon receptor (Aryl Hydrocarbon Receptor, AHR) is a ligand-dependent transcription factor, whose functions are related to xenobiotic detoxification, response to inflammation, and maintenance of tissue homeostasis. Recent investigations suggest that AHR also plays an important role in the processes of carcinogenesis. Increased expression of AHR is observed in several types of tumors and tumor cell lines. In addition, it turned out that the composition of pharmaceutical drugs used in oncotherapy includes some ligands AHR. These facts allow us to consider an aryl-hydrocarbon receptor as a potential target for anticancer therapy, especially for the treatment of severe cancers whose treatment options are very limited or do not exist at all. In this review the examples of AHR ligands' effect on tumor cell cultures and on model mice lines with AHR-dependent response are discussed.
Download PDF:  
Keywords: aryl-hydrocarbon receptor AHR, anticancer therapy, ligands, cell culture, oncology

Vorontsova, J. E., Cherezov, R. O., Kuzin, B. A., Simonova, O. B. (2018). Aryl-hydrocarbon receptor as a potential target for anticancer therapy. Biomeditsinskaya Khimiya, 64(5), 397-415.
This paper is also available as the English translation: 10.1134/S1990750819010116
 2024 (vol 70)
 2023 (vol 69)
 2022 (vol 68)
 2021 (vol 67)
 2020 (vol 66)
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)